Michael Ehlers, Biogen via Youtube
October 1, 2019 08:33 AM EDTUpdated 10:18 AM
R&D

Michael Ehlers jumps a list­ing ship, turn­ing to VC and star­tups as a dam­aged Bio­gen taps long­time vet Al San­drock to take his place

John Carroll

Editor & Founder

Al San­drock Bio­gen

Just a lit­tle more than 3 years af­ter Michael Ehlers took the lead job as glob­al head of R&D for the now deeply trou­bled Bio­gen, he’s jump­ing ship. And CEO Michel Vounatsos is nam­ing CMO Al San­drock, the ar­chi­tect of a deeply flawed pipeline strat­e­gy, as his re­place­ment.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

A service from the Financial Times